PMID- 26559285
OWN - NLM
STAT- MEDLINE
DCOM- 20160301
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 45
DP  - 2015 Nov
TI  - Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly 
      Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis.
PG  - e1989
LID - 10.1097/MD.0000000000001989 [doi]
LID - e1989
AB  - To investigate the cost-effectiveness of different screening intervals for 
      diabetic retinopathy (DR) in Chinese patients with newly diagnosed type 2 
      diabetes mellitus (T2DM). Chinese healthcare system.Chinese general clinical 
      setting. A cost-effectiveness model was developed to simulate the disease course 
      of Chinese population with newly diagnosed with diabetes. Different DR screening 
      programs were modeled to project economic outcomes. To develop the economic 
      model, we calibrated the progression rates of DR that fit Chinese epidemiologic 
      data derived from the published literature. Costs were estimated from the 
      perspective of the Chinese healthcare system, and the analysis was run over a 
      lifetime horizon. One-way and probabilistic sensitivity analyses were performed. 
      Total costs, vision outcomes, costs per quality-adjusted life year (QALY), the 
      incremental cost-effectiveness ratio (ICER) of screening strategies compared to 
      no screening. DR screening is effective in Chinese patients with newly diagnosed 
      T2DM, and screen strategies with >/=4-year intervals were cost-effective (ICER 
      <$7,485 per QALY) compared to no screening. Screening every 4 years produced the 
      greatest increase in QALYs (11.066) among the cost-effective strategies. The 
      screening intervals could be varied dramatically by age at T2DM diagnosis. 
      Probabilistic sensitivity analyses demonstrated the consistency and robustness of 
      the cost-effectiveness of the 4-year interval screening strategy. The findings 
      suggest that a 4-year interval screening strategy is likely to be more 
      cost-effective than screening every 1 to 3 years in comparison with no screening 
      in the Chinese setting. The screening intervals might be tailored according to 
      the age at T2DM diagnosis.
FAU - Wu, Bin
AU  - Wu B
AD  - From the Medical Decision and Economic Group, Department of Pharmacy (BW); 
      Department of Ophthalmology, Ren Ji Hospital, affiliated with the School of 
      Medicine, Shanghai Jiaotong University, Shanghai (JL); and Department of 
      Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China (HW).
FAU - Li, Jin
AU  - Li J
FAU - Wu, Haixiang
AU  - Wu H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - China
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Retinopathy/*diagnosis
MH  - Humans
MH  - Mass Screening/*economics
MH  - Middle Aged
MH  - Models, Economic
PMC - PMC4912279
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2015/11/13 06:00
MHDA- 2016/03/02 06:00
PMCR- 2015/11/13
CRDT- 2015/11/13 06:00
PHST- 2015/11/13 06:00 [entrez]
PHST- 2015/11/13 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
PHST- 2015/11/13 00:00 [pmc-release]
AID - 00005792-201511110-00040 [pii]
AID - 10.1097/MD.0000000000001989 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Nov;94(45):e1989. doi: 10.1097/MD.0000000000001989.